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ed June 3, 2013.his study sought to examine the prevalence and clinical implications of morbid obesity among patients undergoing
percutaneous coronary intervention (PCI).Background Theprevalenceof obesity, andmorbid obesity in particular, continues to rise rapidly in theUnitedStates. Obesepatients
are at increased risk for cardiac disease and are more likely to need invasive cardiac procedures. There is a paucity of
contemporary data on the prevalence and clinical implications of morbid obesity among patients undergoing PCI.Methods We examined the prevalence of morbid obesity (body mass index [BMI] 40 kg/m2) among 227,044 patients
undergoing PCI and enrolled in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium registry from
1998 to 2009.Results The proportion of morbidly obese patients undergoing PCI increased from 4.38% in 1998 to 8.36% in 2009.
Compared with overweight patients (BMI 25 to 30 kg/m2), these patients had signiﬁcantly increased vascular
complications (adjusted odds ratio [OR]: 1.31; 95% CI: 1.17 to 1.47; p < 0.0001), contrast-induced nephropathy
(adjusted OR: 1.89; 95% CI: 1.70 to 2.11; p < 0.0001), nephropathy requiring dialysis (adjusted OR: 4.08; 95%
CI: 2.98 to 5.59; p < 0.0001), and mortality (adjusted OR: 1.63; 95% CI: 1.33 to 2.00; p < 0.0001).Conclusions Morbid obesity is increasing in prevalence among patients undergoing PCI and is associated with a higher risk of
mortality and morbidity. These epidemiological changes have important implications for technical considerations of
cardiac catheterization, design of the catheterization lab to accommodate these patients, and most importantly, for
societal effort toward prevention of obesity. (J Am Coll Cardiol 2013;62:685–91) ª 2013 by the American College
of Cardiology FoundationObesity is a rapidly increasing worldwide epidemic. In
2010, 35.7% of all adults over 18 years of age were obese
(body mass index [BMI] 30 kg/m2) (1) compared with
12% of all adults in 1991 and 17.9% in 1998 (2). ObeseMedicine, University of Michigan, Ann Arbor,
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, 2012; revised manuscript received May 31,patients are at increased risk for cardiac disease and are more
likely to require invasive cardiac procedures (3). However,
multiple studies have shown that obesity has a paradoxical
protective effect on outcomes after percutaneous coronary
intervention (PCI) (4,5).
Although there have been many studies on the outcomes of
obese patients undergoing PCI, there are limited data about the
prevalence and health outcomes of the morbidly obese
(BMI 40 kg/m2). One small study estimated that the prev-
alence of morbidly obese adults has increased from 2.20% in
2001 to 3.07% in 2005 in the general U.S. population (6). It is
likely that the increasing prevalence ofmorbid obesity in society
will translate into an increase in the prevalence of morbid
obesity among patients with cardiovascular disease. There is
a paucity of data on the prevalence and implications of morbid
Table 1
Baseline Characte
Morbidly Obese
Variable
Demographic
Age, yrs
Age 60–69 yrs
Age 70–79 yrs
Age 80 yrs
Female
Current smoker
GFR 60–89 ml/min/1.73 m2
GFR 30–59 ml/min/1.73 m2
GFR <30 ml/min/1.73 m2
Historical
Hypertension
MI
Diabetes mellitus
Congestive heart failure
Extracardiac vascular disease
Signiﬁcant valve disease
Renal failure on dialysis
Gastrointestinal bleeding
Atrial ﬁbrillation
PCI
CABG
Chronic obstructive pulmonary dis
Abbreviations
and Acronyms
BMI = body mass index
CABG = coronary artery
bypass grafting
CIN = contrast-induced
nephropathy
MI = myocardial infarction
NRD = nephropathy requiring
dialysis
PCI = percutaneous coronary
intervention
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686obesity among patients under-
going PCI. This study examined
the prevalence of morbid obesity
amongpatients presenting for PCI
between 1998 and 2009 and ex-
amined complications in morbidly
obese patients.Methods
The study population comprised
227,044 patients undergoing PCI
and enrolled in the Blue Cross
Blue Shield of Michigan Cardio-vascular Consortium (BMC2) registry from 1998 to 2009. The
details of the BMC2 registry, data collection, and auditing have
been previously documented and are detailed in the Online
Appendix (7–9).
Patients were divided into 4 categories according to BMI
(kg/m2): lean (BMI <25), overweight (25 BMI <30),
submorbidly obese (30 BMI <40), and morbidly obese
(BMI 40). The primary outcome of interest was the
change in prevalence of morbidly obese patients from 1998
to 2009. We also compared the in-hospital outcomes across
the 4 categories of BMI, with the speciﬁc outcomes being
in-hospital death, emergency coronary artery bypass graft-
ing (CABG), all CABG, contrast-induced nephropathyristics of Patients Categorized by Body M
Lean
(n ¼ 43,346)
Overw
(n ¼ 82
68.0  13 64.9
22.5 26.
28.3 26.
21.8 12.
40.8 28.
31.5 26.
36.9 45.
42.8 28.
5.6 2.
73.8 76.
35.1 34.
20.6 26.
15.5 11.
29.1 23.
6.1 4.
2.9 1.
2.7 1.
11.0 8.
38.3 41.
18.9 20.
ease 21.8 15.(CIN), nephropathy requiring dialysis (NRD), post-
procedure transfusion, stroke/transient ischemic attack,
myocardial infarction (MI), major adverse cardiac events,
vascular complications, and gastrointestinal bleeding.
In-hospital death was deﬁned as death from cardiac or
noncardiac causes during the same admission as that for
PCI. Vascular complications were deﬁned as a composite
of pseudoaneurysm, arteriovenous ﬁstula, femoral
neuropathy, retroperitoneal hematoma, access site hema-
toma requiring transfusion or associated with prolonged
hospital stay, drop in hemoglobin >3.0 g/dl, or any access
site complication requiring surgical repair. CIN was
deﬁned as a creatinine increase 0.5 mg/dl above baseline
(10). Major adverse cardiac events was deﬁned as
a composite of death, stroke/transient ischemic attack,
MI, all CABG, and revascularization involving the index
lesion.
Statistical analysis. Continuous variables were expressed as
mean  SD, and discrete variables were expressed as
frequency counts and percentages. Secular changes in the
proportion of morbidly obese patients presenting for
PCI were assessed with the Cochrane-Armitage test.
We developed multiple hierarchical models to assess
the impact of BMI categories on different outcomes of
interest using overweight patients (the group that has tradi-
tionally demonstrated the best post-PCI outcomes) as
the reference. The pre-procedural variables demonstratingass Index as Lean, Overweight, Submorbidly Obese, and
Weight Category
p Value
eight
,487)
Submorbidly Obese
(n ¼ 84,479)
Morbidly Obese
(n ¼ 16,730)
 12 62.0  11 59.2  11 <0.0001
8 30.1 32.1 <0.0001
3 21.2 14.4 <0.0001
5 6.2 2.4 <0.0001
1 33.9 49.5 <0.0001
5 25.0 22.4 <0.0001
2 39.8 26.6 <0.0001
8 17.7 10.0 <0.0001
1 1.1 0.6 <0.0001
3 83.6 89.7 <0.0001
3 34.9 34.9 0.01
8 41.8 60.5 <0.0001
5 13.6 20.9 <0.0001
2 22.0 22.5 <0.0001
1 3.1 2.4 <0.0001
7 1.6 2.0 <0.0001
7 1.5 1.5 <0.0001
8 8.3 8.6 <0.0001
3 43.7 42.9 <0.0001
4 19.5 15.6 <0.0001
1 16.6 22.3 <0.0001
Continued on the next page
Table 1 Continued
Variable
Weight Category
p Value
Lean
(n ¼ 43,346)
Overweight
(n ¼ 82,487)
Submorbidly Obese
(n ¼ 84,479)
Morbidly Obese
(n ¼ 16,730)
Presenting
MI present (<7 days prior) 35.7 31.4 28.2 26.4 <0.0001
Acute MI (<24 h prior) 19.9 18.2 15.8 13.4 <0.0001
Cardiogenic shock 3.1 2.0 1.5 1.4 <0.0001
Cardiac arrest 2.3 2.1 1.7 1.7 <0.0001
Ventricular tachycardia/ﬁbrillation 1.8 1.6 1.3 1.0 <0.0001
Emergent PCI 17.8 15.7 13.1 11.1 <0.0001
Laboratory
Femoral access 98.4 98.7 98.7 97.1 <0.0001
Radial access 0.91 0.92 0.96 1.92 <0.0001
Baseline creatinine, mg/dl 1.22  1.2 1.17  1.0 1.16  0.9 1.17  1.2 <0.0001
Baseline creatinine >1.5 mg/dl 12.6 10.6 10.8 12.3 <0.0001
Post-procedural peak creatinine, mg/dl 1.31  1.4 1.24  1.2 1.23  1.3 1.28  1.2 <0.0001
Baseline hemoglobin, g/dl 13.1  1.4 13.7  1.9 13.7  1.9 13.3  1.9 <0.0001
Post-procedural hemoglobin, g/dl 11.6  2.1 12.3  2.0 12.4  2.1 12.1  2.1 <0.0001
Anemia 36.6 27.8 26.3 31.1 <0.0001
Diagnostic
Ejection fraction 50.2  12.9 51.7  11.8 52.4  1.4 52.4  11.4 <0.0001
Total contrast volume, ml 202  88 209  90 214  92 220  96 <0.0001
Total ﬂuoroscopy time, min 15.3  13 15.0  13 14.8  12 14.7  12 <0.0001
Left main stenosis >70% 4.0 3.9 3.2 2.5 <0.0001
Restenotic lesion 7.2 7.4 8.1 8.4 <0.0001
Thrombus 15.8 15.8 14.1 11.9 <0.0001
Calciﬁcation 20.2 17.1 15.7 14.8 <0.0001
Chronic total occlusion 7.7 8.4 7.7 5.2 <0.0001
Lesion in graft 2.1 2.3 2.5 2.7 <0.0001
Pre-procedure medication
Aspirin 92.3 93.5 93.5 92.9 <0.0001
Clopidogrel 44.6 45.3 46.4 46.4 <0.0001
Statins 47.8 52.9 56 56.9 <0.0001
Beta-blockers 65.7 67.9 70.4 71.0 <0.0001
Angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker
40.2 42.5 49.2 55.6 <0.0001
Calcium channel blocker 17.2 16.7 19.3 20.9 <0.0001
Oral nitrate 70.1 70.5 71.2 72.5 <0.0001
Heparin 38.0 35.4 33.9 31.8 <0.0001
Post-procedure medication
Aspirin 94.8 95.9 96.1 95.6 <0.0001
Clopidogrel 91.4 92.5 93 93.6 <0.0001
Statins 73.8 78.4 79.5 79.3 <0.0001
Beta-blocker 80.7 82.7 83.5 83.3 <0.0001
Angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker
59.7 61.9 66.9 71.5 <0.0001
Calcium channel blocker 17.1 16.9 19.8 21.5 <0.0001
Oral nitrate 34.6 33.4 34.7 36.8 <0.0001
Heparin 8.9 7.7 6.8 6.24 <0.0001
Warfarin 9.3 8.5 8.8 10.1 <0.0001
Days from procedure to discharge, mean 3.55 3.47 3.01 3.13 <0.0001*
Values are mean  SD or %. *Kruskal-Wallis test.
CABG ¼ coronary artery bypass graft; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
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687marginal association (p < 0.1) with the speciﬁc outcome of
interest were selected through stepwise selection and in-
cluded demographic information, comorbidities, presenting
cardiac diagnosis, laboratory variables, and angiographic
ﬁndings. Model discrimination was assessed using theC-statistic, and calibration was assessed using the Hosmer
Lemeshow test. The variables included in the ﬁnal models
are listed in the Online Appendix. All analysis was performed
using SAS version 9.2 (SAS Institute, Cary, North
Carolina).
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688Results
Our study enrolled 227,042 patients, of whom 19.1%
(n ¼ 43,346) were in the lean category, 36.3% (n ¼ 82,487)
were in the overweight category, 37.2% (n ¼ 84,479) were in
the submorbidly obese category, and 7.4% (n ¼ 16,730)
were in the morbidly obese group. The baseline character-
istics of the population are detailed in Table 1. Among the
32 hospitals, the prevalence of morbid obesity ranged from
5.0% to 11.4% (Online Fig. 1).
The morbidly obese group was overall signiﬁcantly
younger (mean age 59.2 years vs. 64.9 years in the over-
weight group) than the other groups, with a male/female
ratio of approximately 1:1. In addition, they were less likely
to be smokers and had a signiﬁcantly higher incidence of
hypertension and diabetes.
The pre- and post-procedure medications are listed in
Table 1. The morbidly obese group was more likely to be
receiving statins, beta-blockers, and angiotensin-converting
enzyme-inhibitors or angiotensin receptor blockers pre-
procedure as compared with the other categories.
Over the course of the study, signiﬁcant changes in the
obesity proﬁle were noted, with a small but signiﬁcant
rightward shift in the BMI distribution (Fig. 1). Between
1998 and 2009, the proportion of lean patients decreased from
22.64% to 18.48%, the overweight patients decreased from
39.38% to 35.07%, the submorbidly obese patients increased
from 33.59% to 38.08%, and the morbidly obese category
increased from 4.38% to 8.36%. There was a 91% increase in
the number of morbidly obese patients presenting for PCI.
The unadjusted and adjusted clinical outcomes of patients
in different BMI categories are listed in Table 2 and
Figure 2. The lean patients had a lower risk of CIN but a
higher risk of post-procedure transfusion, vascular compli-
cations, and death. The submorbidly obese category had an
increased risk of CIN, NRD, and vascular complicationsFigure 1 BMI Trends for Lean, Submorbidly Obese, and Morbidly Obe
The proportion of patients classiﬁed as lean or overweight has declined, whereas there h
BMI ¼ body mass index.compared with the overweight group. Finally, the morbidly
obese patients had a lower risk of emergent CABG and all
CABG but an increased risk of CIN, NRD, vascular
complications, and death.
Discussion
The key ﬁnding of our study was that there has been a sig-
niﬁcant increase in the proportion of morbidly obese patients
undergoing PCI. Second, these patients have a markedly
increased adjusted risk of complications, suggesting that
the obesity paradox does not appear to be protective in this
population. The ﬁndings of our study, derived from a large
unselected population of 227,044 patients, signiﬁcantly adds
to the prior work evaluating the impact of obesity on PCI
outcomes.
A large body of data suggests that obesity is a growing
epidemic in the general population, and our study suggests that
this has been accompanied by an increase in the obesity proﬁle
of the patients undergoing PCI. There has been a steady
increase in the proportion of patients who are submorbidly and
morbidly obese, with the submorbidly obese population
making up the largest cohort of patients in recent years.
Several studies have demonstrated that overweight
patients have a lower risk of cardiovascular events and all-
cause mortality than normal-weight patients (5,11). These
results have not only been conﬁrmed in overweight patients
with coronary artery disease but also in overweight patients
with heart failure as well (12). There has been an increasing
focus on the obesity paradox in both the medical and the lay
press (13). However, the term “obesity paradox” obfuscates
the adverse outcomes associated with morbid obesity,
a group that was at signiﬁcantly higher risk of mortality and
morbidity in our study.
The increase in complications may be due to many
reasons. The increase in the risk of CIN and NRD isse Versus Overweight Patients From 1998 to 2009
as been an increase in those classiﬁed as submorbidly obese or morbidly obese.
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689probably directly related to the increased use of contrast
media in this population (14). The poor ﬂuoroscopic visu-
alization associated with obesity often necessitates multiple
contrast injections, with increased risk of renal complica-
tions. Second, calculation of renal function in morbidly
obese patients may be erroneous because the commonly used
methods of calculating glomerular ﬁltration rate or creati-
nine clearance to guide contrast dosing have not been vali-
dated in and may not be applicable to patients with extreme
body mass.
The increase in vascular complications in the morbidly
obese is not surprising because the majority of patients
underwent transfemoral PCI, for which both access and
vascular closure would be more difﬁcult with increasing body
mass. Although radial access was rarely employed in this
population, there has been a more recent upsurge in the use
of radial access, and it would be interesting to assess if
increasing use of radial PCI will negate the impact of BMI
on vascular complications.
The most important clinical outcome was the increased
risk of death in the morbidly obese patients. This is espe-
cially concerning because the obese patients were signiﬁ-
cantly younger than other patients and were more likely to
be undergoing PCI for stable disease.
Further, as compared with overweight patients, the
morbidly obese patients had better baseline left ventricular
ejection fraction and lower incidence of acute MI, cardio-
genic shock, and need for emergent PCIdall of the factors
that are traditionally associated with a lower mortality risk in
patients undergoing PCI. Our ﬁndings corroborate a recent
study demonstrating that morbidly obese patients presenting
with ST-segment elevation myocardial infarction had
a higher mortality despite being younger and having better
left ventricular function and less extensive coronary artery
disease (15). This increased risk despite the presence of
lower-risk features suggests that factors other than the
traditional risk factors for post-PCI mortality may play a role
in this population. Further, it is possible that these patients
may have altered pharmacokinetics of the commonly used
periprocedural medications and may demonstrate a differing
response to ischemic challenges. Finally, the suboptimal
radiographic visualization that is occasionally encountered in
morbidly obese patients may preclude detection of less than
ideal angiographic results, which may potentially result in
a greater likelihood of ischemic complications. Our study
was not designed to elucidate the reasons for the increased
mortality observed in this population, and these conjectures
should be considered hypothesis generating.
It is also possible that the dramatically increased incidence
of diabetes in this population contributed to both develop-
ment of coronary artery disease and the adverse outcome
following PCI seen in this population. Further research is
warranted to identify the mechanistic underpinning of this
association.
Finally, the dramatic increase in the number of morbidly
obese patients has important implications for technical
Figure 2
Adjusted Odds Ratio for Adverse Hospital Outcomes for Lean, Submorbidly Obese, and
Morbidly Obese Versus Overweight Patients
The adjusted odds of contrast-induced nephropathy (CIN), death, vascular complications (vasc comp), or nephropathy requiring dialysis (NRD) in lean, submorbidly obese,
and morbidly obese patients compared with overweight patients. The adjusted odds for all complications were higher in the morbidly obese patients.
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690considerations of cardiac catheterization and design of the
catheterization laboratory to accommodate these patients.
The need to deal with increasing body weight will require
catheterization tables with greater weight tolerance and
systems to safely transfer patients to and from these tables.
Further, better radiation shielding and consideration of
alternative imaging strategies need to be considered because
these patients and their physicians are exposed to increased
radiation. Furthermore, the dramatic increase in the
proportion of young patients with morbid obesity invokes
the need for more upstream interventions for primary
prevention and better treatment of obesity.
Study limitations. The major limitations of this study are
that it only included nonrandomized patients and offered
observational data. There is an unaccounted bias in which
certain morbidly obese patients were selected for revascu-
larization and in the revascularization strategies offered to
these patients. There may also be selection bias in that
morbidly obese patients may have been offered PCI more
often than surgical revascularization. Additionally, it is
possible that operator experience overall and speciﬁcally in
performing PCI in morbidly obese patients may be an
important predictor of outcome. Our study was unable to
account for this variable. Finally, this study examined the
prevalence of obesity in a single state, the ﬁfth most obese
state in 2011, and results may not be extrapolated to the
remainder of the United States (16).
Conclusions
This large study analyzed 227,044 patients and found that
there has been a 91% increase in the number of morbidly
obese patients presenting for PCI from 1998 to 2009. The
prevalence of morbidly obese patients is growing at a fasterrate than overweight or obese patients. The morbidly obese
patients have an increased risk of CIN, NRD, vascular
complications, and death despite being younger and having
a more stable presentation than overweight patients. The
ﬁndings of our study have important implications for
contemporary interventional practice and prevention and
treatment of obesity.
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